Agenda
Keynote Speaker:
Alan List, M.D., President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Friday, July 12, 2019
Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI
Tom Misteli, Ph.D., Center for Cancer Research, NCI
Alan List, M.D., Moffit Cancer Center
Moderator: Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI
WHO MDS Classification
Katherine Calvo, M.D., Ph.D., Clinical Center, NIH
Overview of MDS Standard Therapy
Catherine Lai, M.D., Lombardi Cancer Center
Moderator: Peter Aplan, M.D., Center for Cancer Research, NCI
Somatic and Germ Line Mutations in AML
Paul Liu, M.D., Ph.D., National Human Genome Research Institute, NIH
Current Status and Advances in MRD Measurement
Christopher Hourigan, M.D., D.Phil., National Heart, Lung, and Blood Institute, NIH
Laura Dillon Ph.D., National Heart, Lung, and Blood Institute, NIH
Preclinical Myeloid Leukemia Models
Peter Aplan, M.D., Center for Cancer Research, NCI
Novel HMAs and Combinations
Steven Grant, M.D., Virginia Commonwealth University
CTEP AML/MDS Precision Medicine Initiative
Rich Little, M.D., Division of Cancer Treatment and Diagnosis, NCI
Moderator: Nirali Shah, M.D., Center for Cancer Research, NCI
Heterogeneity in Refractory AML
Michael Gottesman, M.D., Center for Cancer Research, NCI
Targeting HMA Refractory MDS
Daniel Larson, Ph.D., Center for Cancer Research, NCI
Strategies to Enhance Effects of Cellular Immunotherapy
Jack Shern, M.D., Center for Cancer Research, NCI
NK Cell Therapy for Myeloid Leukemia
Kate Stringaris, M.D., Ph.D., National Heart, Lung and Blood Institute, NIH
Chemotherapy Induced AML in Modern Era
Lindsay Morton, Ph.D., Division of Cancer Epidemiology and Genetics, NCI
Moderator: Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
DCTD Phase 1 Program
Geraldine O’Sullivan, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI
Clofarabine and Bortezomib Phase 1 Study
Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI
Sabrina Khan, M.D., MPH, Center for Cancer Research, CCR
CSF1R Blockade
Rosandra Kaplan, M.D., Center for Cancer Research, NCI
MUD RIC Transplant for Hematologic Malignancy
Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
Haplo-Identical Donor Transplant for Hematologic Malignancy
Christopher Kanakry, M.D., Center for Cancer Research, NCI
CAR-T Cells for Acute Leukemia
Nirali Shah, M.D., Center for Cancer Research, NCI
Moderator: Lea Cunningham, M.D., National Human Genome Research Institute, NCI
Allogeneic Transplant for GATA2 Mutation
Mark Parta, Ph.D., National Institute of Allergy and Infectious Diseases, NIH
RUNX1 Clinic and Transplant Protocols
Lea Cunningham, M.D., National Human Genome Research Institute, NCI
Other Inherited Leukemias
Lisa McReynolds, M.D., Ph.D., Division of Cancer Epidemiology and Genetics, NCI